[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"periventricular-leukomalacia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:periventricular-leukomalacia":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,50],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100479236","spinal-stimulation-and-mobility-devices-100479236",false,"NCT05520359","Spinal Stimulation and Mobility Devices","Transcutaneous Stimulation and Mobility Device Use for Individuals With Neurologic Conditions","Inclusion Criteria:\n\n* have a neurologic condition\n* are 4-70 years of age\n* have stable medical condition\n* can perform simple cued motor tasks and who can follow 2-3 step commands\n* who are volunteering to be involved in this study\n* can provide feedback on comfort and experience during lab visits\n\nExclusion Criteria:\n\n* have significant medical disease; including uncontrolled systemic hypertension with values above 170\u002F100 mmHg; cardiac or pulmonary disease; uncorrected coagulation abnormalities or need for therapeutic anticoagulation.\n* have cardiovascular or musculoskeletal disease or injury that would prevent full participation in physical therapy intervention\n* have a history of uncontrolled seizures\n* have unhealed fracture or other musculoskeletal impairment that might interfere with lower extremity rehabilitation or testing activities\n* are dependent on ventilation support\n* have implanted stimulator (e.g. epidural stimulator, vagus nerve stimulator, pacemaker, cochlear implant, etc) or drug delivery device (e.g. baclofen pump)\n* have history of orthopedic surgery in lower extremities or neurosurgery that may be a confounding factor for interpretation of the results (such as tendon transfer, tendon or muscle lengthening for spasticity management, injection therapies to lower extremity muscles, etc.) in last 12 months\n* have established osteoporosis and taking medication for osteoporosis treatment.\n* have rheumatic diseases (rheumatoid arthritis, systemic lupus erythematosus, etc.)\n* have active cancer","ALL","4 Years","70 Years",{"count":20,"type":21},20,"ESTIMATED","INTERVENTIONAL",[24],"NA","This research study will combine non-invasive spinal stimulation with mobility devices to examine the acute impact of the individual and combined effects of these innovative techniques on mobility in children with cerebral palsy.",[27,28,29,30,31],"Cerebral Palsy","Stroke","Premature Birth","Hypoxic-Ischemic Encephalopathy","Periventricular Leukomalacia",[33,34,35,36],"Pediatric","Mobility Aids","Assistive Technology","Spinal Stimulation","RECRUITING","2025-08-11",{"date":40,"type":41},"2025-08-13","ACTUAL",{"date":43,"type":41},"2022-08-04",{"date":45,"type":21},"2026-12-31",{"name":47,"class":48},"University of Washington","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":61,"conditions":62,"keywords":68,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":75,"leadSponsor":77,"locationsCount":4},"100519559","pufas-in-preterm-infants-100519559","NCT06045130","PUFAs in Preterm Infants","Characteristics of PUFAs Composition in Preterm Infants and Its Impact on Disease Prognosis","PIPI","Inclusion Criteria:\n\nInfants born between 24 and 36 weeks of gestational age who are admitted within 24 hours of birth, including both premature and full-term newborns.\n\n\\-\n\nExclusion Criteria:\n\nInfants with severe congenital developmental abnormalities, those requiring external supplementation of PUFAs in addition to standard intravenous nutrition and breastfeeding, and those with a severe prognosis indicating non-survival during their hospitalization.\n\n\\-",{"count":59,"type":21},600,"OBSERVATIONAL","The research endeavors to examine the critical composition of Polyunsaturated Fatty Acids (PUFAs) in premature infants across different gestational stages and under varying disease conditions, and delineate the metabolic attributes of PUFAs in premature infants and their interplay with the onset of diseases. This study anticipates furnishing a theoretical foundation for the rationalization of PUFAs supplementation in premature infants and for informing strategies related to disease prevention and management.",[63,64,65,66,31,67],"Necrotizing Enterocolitis","Intraventricular Hemorrhage","BPD - Bronchopulmonary Dysplasia","Sepsis","Patent Ductus Arteriosus",[69],"PUFAs","NOT_YET_RECRUITING","2023-09-13",{"date":73,"type":41},"2023-09-21",{"date":73,"type":21},{"date":76,"type":21},"2026-08-31",{"name":78,"class":48},"The First Hospital of Jilin University"]